CN111991560B - Method for enhancing light stability of isoorientin and application thereof - Google Patents
Method for enhancing light stability of isoorientin and application thereof Download PDFInfo
- Publication number
- CN111991560B CN111991560B CN202010737164.8A CN202010737164A CN111991560B CN 111991560 B CN111991560 B CN 111991560B CN 202010737164 A CN202010737164 A CN 202010737164A CN 111991560 B CN111991560 B CN 111991560B
- Authority
- CN
- China
- Prior art keywords
- isoorientin
- silver nanoparticle
- silver
- solution
- enhancing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for enhancing light stability of isoorientin and application thereof, and belongs to the technical field of chemical material performance improvement.
Description
Technical Field
The invention belongs to the technical field of chemical material performance improvement, relates to improvement of isoorientin performance, and particularly relates to a method for enhancing the light stability of isoorientin and application of the isoorientin.
Background
Isoorientin is a tetrahydroxyflavone compound, also called 3 ', 4', 5, 7-tetrahydroxyflavone-6-O-beta-D-glucopyranoside or luteolin 6-C-glucoside, and has molecular formula of C 21 H 2 OO 11 Molecular weight is 448.38, and its chemical structural formula is shown in FIG. 1. The isoorientin solid is light yellow powder, the steam density is 15.48, and the melting point/freezing point is 237-239 ℃. It is widely contained in food such as cucumber, buckwheat, passion flower, etc., and has antioxidant, antiinflammatory, antibacterial, liver protecting, and intestinal flora regulating effects. But the isoorientin has limited application due to the performance of isoorientin, such as:
1. isoorientin is extremely unstable and can be easily photolyzed, and the biological activity of isoorientin is greatly reduced in a bright environment, so that the application of isoorientin in the pharmaceutical industry is limited;
2. the isoorientin is difficult to be absorbed by human bodies due to poor water solubility, and the application of the isoorientin in the food industry is limited.
Disclosure of Invention
Aiming at the problems of extremely unstable isoorientin, easy photolysis, poor water solubility and the like, the invention provides a method for enhancing the light stability of isoorientin and application thereof, the prepared isoorientin-silver nanoparticle compound has good biological safety, can better inhibit the activity of alpha-glucosidase and pancreatic lipase, and has the effect of preventing diabetes and obesity, and the specific technical scheme is as follows:
the method for enhancing the light stability of isoorientin is characterized in that dispersed silver nanoparticles are used as carriers, so that isoorientin is attached to the surfaces of the silver nanoparticles to form an isoorientin-silver nanoparticle compound with good light stability.
The preparation method of the isoorientin-silver nanoparticle compound comprises the following steps:
1) mixing a corn starch water solution, a silver nitrate water solution and a sodium citrate water solution according to a volume ratio of 20-60: 50-99: 3-8, reacting in a water bath, stirring, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles obtained in the step 1) with ultrapure water, adding the dispersion into the isoorientin solution, stirring under a water bath condition, cooling, centrifuging, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle compound.
Further limiting, the mass concentration of the corn starch aqueous solution is 1-3%, the molar concentration of the silver nitrate aqueous solution is 1-2 mM, and the molar concentration of the sodium citrate aqueous solution is 0.01-0.03 mol/L.
Further limiting, the temperature of the water bath reaction in the step 1) is 60-80 ℃.
Further limiting, the mass concentration of the isoorientin solution in the step 2) is 0.1-2 mg/mL.
Further limiting, the temperature of the water bath in the step 2) is 20-40 ℃.
The isoorientin-silver nanoparticle complex prepared by the preparation method of the isoorientin-silver nanoparticle complex.
The isoorientin-silver nanoparticle complex is applied to inhibiting cytotoxicity.
The isoorientin-silver nanoparticle complex is applied to the aspect of inhibiting the activity of alpha-glucosidase.
The isoorientin-silver nanoparticle complex is applied to the inhibition of pancreatic lipase activity.
Compared with the prior art, the invention has the beneficial effects that:
1. according to the method for enhancing the light stability of isoorientin, isoorientin is attached to the surfaces of silver nanoparticles to form the silver nanoparticles loaded with the isoorientin, namely the isoorientin-silver nanoparticle complex is formed, the isoorientin-silver nanoparticle complex still contains 98.4% of isoorientin after being irradiated by an ultraviolet lamp for 1 hour, and compared with the pure isoorientin, the stability of the isoorientin is greatly improved.
2. The isoorientin-silver nanoparticle compound prepared by the invention is simple in preparation process, and the isoorientin-silver nanoparticle compound can well inhibit cytotoxicity and has good biological safety; meanwhile, the isoorientin-silver nanoparticle compound can inhibit the activities of alpha-glucosidase and pancreatic lipase, increases the water solubility of isoorientin, is easier to absorb by a human body, enables the inhibition rate of the isoorientin on the activities of the alpha-glucosidase and the pancreatic lipase to be not less than 57% and 19.4%, can play roles in preventing diabetes and obesity, and can be better applied to the pharmaceutical industry and the food industry.
Drawings
FIG. 1 shows the chemical structure of isoorientin;
fig. 2 is an ultraviolet absorption spectrum of isoorientin and isoorientin-silver nanoparticle complexes;
fig. 3 is a fourier infrared spectrum of isoorientin and isoorientin-silver nanoparticle composites;
fig. 4 is a transmission electron microscope image of isoorientin and isoorientin-silver nanoparticle complexes;
fig. 5 is a photostability chart of isoorientin and isoorientin-silver nanoparticle complexes;
fig. 6 shows the action of isoorientin and isoorientin-silver nanoparticle complexes on human hepatocyte viability;
fig. 7 shows the influence of isoorientin and isoorientin-silver nanoparticle complexes on the activity of alpha-glucosidase;
fig. 8 shows the effect of isoorientin and isoorientin-silver nanoparticle complexes on pancreatic lipase activity.
Detailed Description
The technical solutions of the present invention will be further explained below with reference to the drawings and examples, but the present invention is not limited to the embodiments explained below.
The method for enhancing the light stability of isoorientin comprises the following steps: the method is characterized in that the isoorientin is attached to the surfaces of silver nanoparticles by using the dispersed silver nanoparticles as carriers to form the isoorientin-silver nanoparticle compound with good light stability.
The preparation method of the isoorientin-silver nanoparticle compound comprises the following steps of:
1) mixing a corn starch water solution, a silver nitrate water solution and a sodium citrate water solution according to a volume ratio of 20-60: 50-99: 3-8, reacting in a water bath, stirring, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles obtained in the step 1) with ultrapure water, adding the dispersion into the isoorientin solution, stirring under a water bath condition, cooling, centrifuging, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle composite.
Preferably, the mass concentration of the corn starch aqueous solution is 1-3%, the molar concentration of the silver nitrate aqueous solution is 1-2 mM, and the molar concentration of the sodium citrate aqueous solution is 0.01-0.03 mol/L.
Preferably, the temperature of the water bath reaction in the step 1) is 60-80 ℃.
Preferably, the mass concentration of the isoorientin solution in the step 2) is 0.1-2 mg/mL.
Preferably, the temperature of the water bath in the step 2) is 20-40 ℃.
The isoorientin-silver nanoparticle complex prepared by the preparation method of the isoorientin-silver nanoparticle complex.
The isoorientin-silver nanoparticle complex is applied to inhibiting cytotoxicity.
The isoorientin-silver nanoparticle compound is applied to the inhibition of the activity of alpha-glucosidase.
The isoorientin-silver nanoparticle complex is applied to the inhibition of pancreatic lipase activity.
Example 1
The preparation method of the isoorientin-silver nanoparticle compound comprises the following steps:
1) mixing a corn starch aqueous solution with the mass concentration of 2%, a silver nitrate aqueous solution with the molar concentration of 1.5mM and a sodium citrate aqueous solution with the molar concentration of 0.02mol/L according to the volume ratio of 30: 66: 4, performing water bath reaction at 70 ℃, stirring for 2 hours, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles prepared in the step 1 with ultrapure water, adding isoorientin solution with the volume of 6mL and the mass concentration of 1mg/mL, stirring for 30 hours under the condition of water bath at the temperature of 30 ℃, centrifuging for 30 minutes at the rotating speed of 10000rmp, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle compound.
Referring to fig. 2, the recombination rate of the isoorientin-silver nanoparticle composite is 76.6% by calculation through ultraviolet spectrum.
Example 2
The preparation method of the isoorientin-silver nanoparticle compound comprises the following steps:
1) mixing a corn starch aqueous solution with the mass concentration of 1%, a silver nitrate aqueous solution with the molar concentration of 1mM and a sodium citrate aqueous solution with the molar concentration of 0.01mol/L according to the volume ratio of 60: 99: 8, performing water bath reaction at 60 ℃, stirring for 1 hour, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles prepared in the step 1 by using ultrapure water, adding isoorientin solution with the volume of 5mL and the mass concentration of 0.1mg/mL, stirring for 48 hours under the water bath condition of 20 ℃, centrifuging for 30 minutes at the rotating speed of 8000rmp, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle composite.
Example 3
The preparation method of the isoorientin-silver nanoparticle compound comprises the following steps:
1) mixing a corn starch aqueous solution with the mass concentration of 3%, a silver nitrate aqueous solution with the molar concentration of 2mM and a sodium citrate aqueous solution with the molar concentration of 0.03mol/L according to the volume ratio of 20: 50: 3, performing water bath reaction at 80 ℃, stirring for 3 hours, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles prepared in the step 1 with ultrapure water, adding an isoorientin solution with the volume of 3mL and the mass concentration of 2mg/mL, stirring for 10 hours under the water bath condition of 40 ℃, centrifuging for 30 minutes at the rotating speed of 12000rmp, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle composite.
To illustrate the performance of the isoorientin-silver nanoparticle composites of the invention, the following tests were performed:
test 1: structural performance index test
Experimental groups: isoorientin-silver nanoparticle complexes prepared in example 1
Control group: silver nanoparticles
Referring to FIG. 3, the Fourier infrared spectra of isoorientin and isoorientin-silver nanoparticle composite show that the infrared spectrum of isoorientin is 3425.3cm -1 And 2941.28cm -1 Has unique peak belonging to O-H and C-H groups of isoorientin, C-O, CThe peaks of C and aromatic C ═ C appeared at 1641.33, 1446.27 and 1431.13cm respectively -1 To (3). The infrared spectrum of the isoorientin-silver nanoparticle composite shows that all representative peaks are at respective positions, and the absorbance changes slightly, so that the isoorientin is successfully loaded on the silver nanoparticles to form the isoorientin-silver nanoparticle composite.
Referring to fig. 4, it can be seen from transmission electron microscope images of the isoorientin and the isoorientin-silver nanoparticle composites that are spherical particles. By comparison, it was found that the particle size of the silver nanoparticles was smaller than that of the isoorientin-silver nanoparticle complex particles under the same magnified visual field.
Test 2: photostability test of isoorientin-silver nanoparticle complexes
Experimental groups: isoorientin-silver nanoparticle composite prepared in example 1
Control group: isoorientin
Referring to fig. 5, it can be seen from the light stability chart of isoorientin and the isoorientin-silver nanoparticle complexes that the concentration of isoorientin is gradually reduced along with the extension of the irradiation time of the ultraviolet lamp, and after the irradiation time is 1 hour, the concentration of isoorientin is only 78.1%, but the concentration of isoorientin in the isoorientin-silver nanoparticle complexes is still 98.4%, and the concentration is almost not changed, which indicates that the isoorientin-silver nanoparticle complexes are not easily photolyzed, i.e., the isoorientin-silver nanoparticle complexes have stronger light stability, and can better maintain the functional activity of isoorientin.
Test 3: biological safety test of isoorientin-silver nanoparticle complex
Experimental groups: isoorientin-silver nanoparticle complexes prepared in example 1
Control group: isoorientin
The cell activity of the isoorientin-silver nanoparticle complex on HL-7702 human liver cells is determined by adopting an MTT staining method.
Referring to fig. 6, the isoorientin and the isoorientin-silver nanoparticle complex have the effect on the activity of human hepatocytes, after the isoorientin and the isoorientin-silver nanoparticle complex with the same concentration are respectively applied to the hepatic cells of the HL-7702, the cell activity of the hepatic cells of the HL-7702 is 132.18%, and after the isoorientin is applied, the cell activity of the hepatic cells of the HL-7702 is 103.87%, which indicates that the isoorientin-silver nanoparticle complex has no influence on the cell activity of the hepatic cells of the HL-7702, i.e., the isoorientin-silver nanoparticle complex does not generate toxicity to the hepatic cells of the HL-7702, and has good biological safety.
The same test method is used for measuring human pancreatic cells, human myocardial cells and human stem cells, the conclusion that the human pancreatic cells, the human myocardial cells and the human stem cells are the same as the human liver cells is obtained, and the isoorientin-silver nanoparticle compound prepared by the invention can well inhibit cytotoxicity and has good biological safety.
Test 4: test for inhibiting activity of alpha-glucosidase by isoorientin-silver nanoparticle complex
Experimental groups: isoorientin-silver nanoparticle complexes prepared in example 1
Control group: isoorientin
Alpha-glucosidase is a membrane-bound enzyme that breaks down carbohydrates in food into glucose, but large amounts of glucose accumulate in the blood leading to diabetes. Therefore, if the activity of alpha-glucosidase is inhibited, diabetes can be prevented.
Adding 80 mu L of isoorientin-silver nanoparticle complex solution with concentration of 60 mu g/mL, 80 mu L of isoorientin-silver nanoparticle complex solution with concentration of 90 mu g/mL, 80 mu L of isoorientin-silver nanoparticle complex solution with concentration of 120 mu g/mL, 80 mu L of isoorientin solution with concentration of 60 mu g/mL, 80 mu L of isoorientin solution with concentration of 90 mu g/mL, 80 mu L of isoorientin solution with concentration of 120 mu g/mL into 6 glucosidase solutions containing 20 mu L of phosphate buffer solution with concentration of 20 mu g/mL and 20 mu g/mL respectively, incubation was carried out at 37 ℃ for 5min, followed by addition of 100. mu.L of 4mM Na followed by addition of 4mM Na to a phosphate buffer solution containing 100. mu.L of 4mM nitrophenyl-beta-D-glucopyranoside and incubation at 37 ℃ for a further 30 min. 2 CO 3 The solution stops the reaction. The absorbance is measured at 412nm by using a microplate reader, and the alpha-glucosidase inhibition rate is calculated according to the following formula:
alpha-glucosidase inhibition ratio (%) (100- (sample absorbance/blank absorbance. times.100))
As can be seen from fig. 7, the inhibition rate of the isoorientin-silver nanoparticle composite on alpha-glucosidase is obviously increased along with the increase of the concentration, and when the concentration is 120 mug/mL, the inhibition rate of the isoorientin-silver nanoparticle composite on alpha-glucosidase is 57%, and the inhibition rate of the isoorientin on alpha-glucosidase is 51%.
Therefore, the isoorientin-silver nanoparticle complex has stronger inhibition capability on the activity of the alpha-glucosidase than isoorientin.
Test 5: test for inhibiting pancreatic lipase activity by isoorientin-silver nanoparticle compound
Experimental groups: isoorientin-silver nanoparticle complexes prepared in example 1
Control group: isoorientin
Pancreatic lipase is an important gastrointestinal enzyme that hydrolyzes triacylglycerols to glycerol and fatty acids, resulting in obesity. Therefore, obesity can be prevented if the activity of pancreatic lipase is inhibited.
Dissolving 5.0mg/mL of pancreatic lipase in 1M tris (hydroxymethyl) aminomethane buffer solution with a pH of 8.5, dissolving 4-nitrophenyl caprylate substrate with dimethyl sulfoxide, diluting with 5.0mM ethanol to prepare a pancreatic lipase solution, adding 100.0mac L of isoorientin-silver nanoparticle complex solution of 8. mu.g/mL, 100.0mac L of isoorientin-silver nanoparticle complex solution of 10. mu.g/mL, 100.0mac L of isoorientin-silver nanoparticle complex solution of 20. mu.g/mL, 100.0mac L of isoorientin-silver nanoparticle complex solution of 8. mu.g/mL, 100.0mac L of isoorientin solution of 10. mu.g/mL, 100.0mac L of isoorientin solution of 20. mu.g/mL, and 20. mu.g/mL of isoorientin solution to 6 parts of 100.0mac L of pancreatic lipase solution, incubating at 37 ℃ for 25min, adding 100.0 mol/L4-nitrophenyl caprylate, incubating at 37 deg.C for 25min, and measuring absorbance at 412nm with microplate reader. The pancreatic lipase inhibition rate was calculated as follows:
pancreatic lipase inhibition (%) is 100- (sample absorbance/blank absorbance. times.100)
As can be seen with reference to figure 8,
with the increase of the concentration, the inhibition rate of the isoorientin-silver nanoparticle complex on pancreatic lipase is obviously increased, and when the concentration is 20 mug/mL, the inhibition rate of the isoorientin-silver nanoparticle complex on pancreatic lipase is 19.4%, and the inhibition rate of isoorientin on pancreatic lipase is 11.4%.
Therefore, the isoorientin-silver nanoparticle complex has stronger inhibition capability on pancreatic lipase activity than isoorientin.
Therefore, the isoorientin-silver nanoparticle complex can be used for inhibiting cytotoxicity, has an obvious inhibition effect on the cytotoxicity and has good biological safety; can also be used for inhibiting the activity of alpha-glucosidase and pancreatic lipase, the inhibition rates of the activity of the alpha-glucosidase and the pancreatic lipase are not less than 57 percent and 19.4 percent respectively, the effects of preventing diabetes and obesity can be achieved, and the preparation method is better applied to the fields of medicine and food.
Claims (6)
1. The method for enhancing the light stability of isoorientin is characterized in that the method is to utilize dispersed silver nanoparticles as carriers to enable the isoorientin to be attached to the surfaces of the silver nanoparticles to form isoorientin-silver nanoparticle complexes with good light stability;
the preparation method of the isoorientin-silver nanoparticle compound comprises the following steps:
1) mixing a corn starch water solution, a silver nitrate water solution and a sodium citrate water solution according to a volume ratio of 20-60: 50-99: 3-8, reacting in a water bath, stirring, centrifuging, and drying the centrifuged precipitate to obtain silver nanoparticles;
2) dispersing the silver nanoparticles obtained in the step 1) with ultrapure water, adding the dispersion into the isoorientin solution, stirring under a water bath condition, cooling, centrifuging, and drying the centrifuged precipitate to obtain the isoorientin-silver nanoparticle compound.
2. The method for enhancing the photo-stability of isoorientin according to claim 1, wherein the mass concentration of the corn starch aqueous solution is 1-3%, the molar concentration of the silver nitrate aqueous solution is 1-2 mM, and the molar concentration of the sodium citrate aqueous solution is 0.01-0.03 mol/L.
3. The method for enhancing the photo-stability of isoorientin according to claim 2, wherein the temperature of the water bath reaction in the step 1) is 60-80 ℃.
4. The method for enhancing light stability of isoorientin according to claim 1, wherein the mass concentration of the isoorientin solution in the step 2) is 0.1-2 mg/mL.
5. The method for enhancing the photo-stability of isoorientin according to claim 4, wherein the temperature of the water bath in the step 2) is 20-40 ℃.
6. The isoorientin-silver nanoparticle composite prepared by the method for enhancing the light stability of isoorientin according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010737164.8A CN111991560B (en) | 2020-07-28 | 2020-07-28 | Method for enhancing light stability of isoorientin and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010737164.8A CN111991560B (en) | 2020-07-28 | 2020-07-28 | Method for enhancing light stability of isoorientin and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111991560A CN111991560A (en) | 2020-11-27 |
| CN111991560B true CN111991560B (en) | 2022-08-30 |
Family
ID=73467793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010737164.8A Active CN111991560B (en) | 2020-07-28 | 2020-07-28 | Method for enhancing light stability of isoorientin and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991560B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116076512B (en) * | 2023-03-16 | 2023-06-02 | 云南省农业科学院生物技术与种质资源研究所 | Application of isoorientin compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018101555A4 (en) * | 2017-12-15 | 2018-11-29 | Northwest Institute Of Plateau Biology, Chinese Academy Of Sciences | Application of isoorientin in the preparation of insulin-resistant related diseases |
| CN110179998A (en) * | 2019-06-06 | 2019-08-30 | 中国科学院长春应用化学研究所 | A kind of nano particle, preparation method and application |
-
2020
- 2020-07-28 CN CN202010737164.8A patent/CN111991560B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018101555A4 (en) * | 2017-12-15 | 2018-11-29 | Northwest Institute Of Plateau Biology, Chinese Academy Of Sciences | Application of isoorientin in the preparation of insulin-resistant related diseases |
| CN110179998A (en) * | 2019-06-06 | 2019-08-30 | 中国科学院长春应用化学研究所 | A kind of nano particle, preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| Silver nanoparticles induce premutagenic DNA oxidation that can be prevented by phytochemicals from Gentiana asclepiadea;A. Hudecová et al;《Mutagenesis》;20120901;第1-11页 * |
| Structural characterization and stability study of green synthesized starch stabilized silver nanoparticles loaded with isoorientin;Xiao Wang et al;《Food Chemistry》;20200809;第338卷;第1-10页 * |
| 异荭草素在多壁碳纳米管修饰碳糊电极上的电化学行为及其测定;邰俊雅 等;《吉林工程技术师范学院学报》;20181130;第34卷(第11期);第94-96页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111991560A (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dong et al. | GSH‐depleted nanozymes with hyperthermia‐enhanced dual enzyme‐mimic activities for tumor nanocatalytic therapy | |
| Cao et al. | Ultrasmall nanozymes isolated within porous carbonaceous frameworks for synergistic cancer therapy: enhanced oxidative damage and reduced energy supply | |
| Guo et al. | Biocompatibility selenium nanoparticles with an intrinsic oxidase-like activity | |
| Sileika et al. | Colorless multifunctional coatings inspired by polyphenols found in tea, chocolate, and wine | |
| Lai et al. | The Mn-modified porphyrin metal-organic framework with enhanced oxidase-like activity for sensitively colorimetric detection of glutathione | |
| Jangi et al. | A novel and reusable multinanozyme system for sensitive and selective quantification of hydrogen peroxide and highly efficient degradation of organic dye | |
| Huang et al. | One-step synthesis of size-tunable gold nanoparticles immobilized on chitin nanofibrils via green pathway and their potential applications | |
| Liu et al. | Arginine-rich peptide/platinum hybrid colloid nanoparticle cluster: A single nanozyme mimicking multi-enzymatic cascade systems in peroxisome | |
| Jangi | Effect of daylight and air oxygen on nanozymatic activity of unmodified silver nanoparticles: Shelf-stability | |
| Khan et al. | Photocatalytic, antimicrobial activities of biogenic silver nanoparticles and electrochemical degradation of water soluble dyes at glassy carbon/silver modified past electrode using buffer solution | |
| Fan et al. | Green synthesis of stable platinum nanoclusters with enhanced peroxidase-like activity for sensitive detection of glucose and glutathione | |
| Zhang et al. | Bio-interface engineering of MXene nanosheets with immobilized lysozyme for light-enhanced enzymatic inactivation of methicillin-resistant Staphylococcus aureus | |
| Zhang et al. | Self-cascade MoS 2 nanozymes for efficient intracellular antioxidation and hepatic fibrosis therapy | |
| Liang et al. | Functionalized natural melanin nanoparticle mimics natural peroxidase for total antioxidant capacity determination | |
| CN111991560B (en) | Method for enhancing light stability of isoorientin and application thereof | |
| Jawaad et al. | Synthesis of silver nanoparticles | |
| Jangi | Biochemical characterization of enzyme-like silver nanoparticles toward nanozyme-catalysed oxidation reactions | |
| CN111920803B (en) | Preparation for improving activity and/or thermal stability of superoxide dismutase and application thereof | |
| Minzanova et al. | Synthesis, properties, and antimicrobial activity of pectin complexes with cobalt and nickel | |
| Pandey et al. | Controlled synthesis of polyethylenimine coated gold nanoparticles: Application in glutathione sensing and nucleotide delivery | |
| Zhang et al. | Engineering biomimetic ATP-responsive Se-containing core-shell cascade nanozyme for efficient tumor combination therapy | |
| Xiong et al. | Dextran-coated Gd-based ultrasmall nanoparticles as phosphatase-like nanozyme to increase ethanol yield via reduction of yeast intracellular ATP level | |
| Mei et al. | Novel dual-emissive fluorescent silicon nanoparticles for detection of enzyme activity in supplements associated with lactose intolerance | |
| Yang et al. | Construction of platinum nanozyme by using carboxymethylcellulose with improved laccase-like activity for phenolic compounds detection | |
| Yu et al. | Recent Development of Copper‐Based Nanozymes for Biomedical Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |